Hi {{lead.First Name:default=edit me}},

Is dependability the primary factor you consider in a research partner? Did you know that Takeda has trusted Sanguine to prospectively procure biospecimens on 40 studies? Our partnership has covered diverse indications, including Fabry disease, Gaucher disease, and Celiac disease. Clearly, we make a good team in implementing critical studies in humans.

Regardless of your pipeline stage (preclinical, translational, clinical) or disease indication you can customize the study size and scope to accelerate results with a prospective in-home collection or clinical site coordination, including:

  • Recallable patients with specific inclusion/exclusion criteria
  • Multiple specimens collected concurrently with a blood draw
  • Leukopaks from patients with confirmed conditions, such as autoimmune disease
  • Preanalytical lab services (PBMC isolation, HLA typing, etc)

If you are contemplating a new study or would like to learn more for a future study, please respond directly to this email or schedule a time on my calendar.

Warm Regards,

Samrina Lamichhane
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com